Tower Research Capital LLC (TRC) - BLACK DIAMOND THERAPEUTICS I ownership

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of BLACK DIAMOND THERAPEUTICS I
ValueSharesWeighting
Q3 2023$22,529
+110.8%
7,850
+271.0%
0.00%
Q2 2023$10,686
+71140.0%
2,116
-72.3%
0.00%
Q1 2023$15
+150.0%
7,627
+120.1%
0.00%
Q4 2022$6
-99.9%
3,465
-18.9%
0.00%
Q3 2022$7,000
-36.4%
4,275
-4.0%
0.00%
Q2 2022$11,000
+10.0%
4,455
+25.2%
0.00%
Q1 2022$10,000
-83.3%
3,558
-68.4%
0.00%
-100.0%
Q4 2021$60,000
+200.0%
11,249
+367.9%
0.00%0.0%
Q3 2021$20,000
-16.7%
2,404
+23.5%
0.00%0.0%
Q2 2021$24,000
-33.3%
1,947
+31.2%
0.00%0.0%
Q1 2021$36,000
-53.8%
1,484
-39.2%
0.00%
-50.0%
Q4 2020$78,000
-81.7%
2,439
-82.8%
0.00%
-60.0%
Q3 2020$427,000
+306.7%
14,140
+466.5%
0.01%
+25.0%
Q2 2020$105,0002,4960.00%
Other shareholders
BLACK DIAMOND THERAPEUTICS I shareholders Q4 2023
NameSharesValueWeighting ↓
Boxer Capital, LLC 2,014,858$17,046,0000.60%
NEA Management Company, LLC 3,449,845$29,186,0000.35%
MPM BioImpact LLC 248,506$2,102,0000.33%
Artal Group S.A. 1,646,517$13,930,0000.31%
RA Capital Management 2,589,904$21,911,0000.30%
Bellevue Group AG 3,463,000$29,297,0000.30%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 760,128$6,431,0000.13%
Ikarian Capital, LLC 150,484$1,272,0000.09%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 44,000$371,0000.09%
Virtus ETF Advisers LLC 16,600$140,0000.06%
View complete list of BLACK DIAMOND THERAPEUTICS I shareholders